Sign In
Buy NBIX
$165.11
+10.27 (+6.63%)
At Close: Jun 03, 2026
Neurocrine Biosciences to Present at Stifel 3rd Annual CNS Day
04:01pm, Thursday, 25'th Mar 2021
SAN DIEGO, March 25, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 3rd Annual CNS Day at 12:30 p.m. Eastern Time on Thursday Apr. 1, 2021.
Why Neurocrine Biosciences Stock Jumped Today
03:34pm, Thursday, 25'th Mar 2021
The stock is being added to a mid-cap index.
NBIX Stock Price Increased Over 13% Intraday: Why It Happened
02:59pm, Thursday, 25'th Mar 2021
The stock price of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has increased by over 13% during intraday trading. This is why it happened.
Neurocrine Biosciences Set to Join S&P MidCap 400; O-I Glass to Join S&P SmallCap 600
06:35pm, Wednesday, 24'th Mar 2021
NEW YORK, March 24, 2021 /PRNewswire/ -- Neurocrine Biosciences Inc. (NASD:NBIX) will replace O-I Glass Inc. (NYSE:OI) in the S&P MidCap 400, and O-I Glass will replace HMS Holdings Corp (NASD:HMSY)
Neurocrine Biosciences to Present New Data Analyses for Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2021
11:00am, Saturday, 20'th Mar 2021
SAN DIEGO, March 20, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present additional positive data from its Phase II CAHlibrate study of crinecerfont,
5 Analyst Favorite Stocks to Buy for Q2 That Could Be Huge Winners
08:03am, Friday, 19'th Mar 2021
Just like that, we are less than two weeks from the end of the first quarter. While it has been a very positive one for investors, the rise in interest rates has brought in much higher volatility and
The Sell-off In Neurocrine Stock Post Luvadaxistat Failure Is Unwarranted
07:00am, Thursday, 11'th Mar 2021
A few months back we discussed why Neurocrine Biosciences stock, a biotech company that develops treatments for neurological and endocrine-related diseases and disorders, looks oversold at $90 levels.
Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference
04:01pm, Tuesday, 09'th Mar 2021
SAN DIEGO, March 9, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Oppenheimer 31st Annual Healthcare Conference at 4:30 p.m. Eastern Time on Tuesday Mar. 16, 202
Sarepta, Vertex & Neurocrine: Out Of Favor Healthcare Stocks To Watch
10:00am, Wednesday, 24'th Feb 2021
Our theme of Out Of Favor Health Care Stocks includes companies that have robust revenue growth and improving margins, and yet have not rallied much over the last year or so, due to Covid-19 related d
Neurocrine Biosciences Upping Marketing Spend To Support Its Platform
08:51am, Tuesday, 09'th Feb 2021
Neurocrine Biosciences Upping Marketing Spend To Support Its Platform
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q4 2020 Results - Earnings Call Transcript
08:55pm, Thursday, 04'th Feb 2021
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q4 2020 Results - Earnings Call Transcript
Recap: Neurocrine Biosciences Q4 Earnings
04:49pm, Thursday, 04'th Feb 2021
Shares of Neurocrine Biosciences (NASDAQ:NBIX) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 13.33% year over year to $0.91, which
Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results
04:01pm, Thursday, 04'th Feb 2021
SAN DIEGO, Feb. 4, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and full-year ended December 31, 2020 and provided full
Neurocrine Sheds Its Parkinson's Gene Therapy Program, While The Street Waits For Ingrezza Reacceleration
01:28pm, Wednesday, 03'rd Feb 2021
Neurocrine has chosen to terminate development of NBIb-1817, the gene therapy for Parkinson's it acquired through its partnership with Voyager.
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
01:32pm, Thursday, 28'th Jan 2021
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
